Medipol Pharmaceutical India Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 01-01-2025
- Paid Up Capital ₹ 8.55 M
as on 01-01-2025
- Company Age 32 Year, 8 Months
- Last Filing with ROC 31 Mar 2020
- Open Charges ₹ 20.90 Cr
as on 01-01-2025
- Satisfied Charges ₹ 8.27 Cr
as on 01-01-2025
About Medipol Pharmaceutical India
The Corporate was formerly known as Kansal Associates Pvt Ltd. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 8.55 M.
The company currently has active open charges totaling ₹20.90 Cr. The company has closed loans amounting to ₹8.27 Cr, as per Ministry of Corporate Affairs (MCA) records.
Umesh Gupta, Sanjay Agarwal, and Yogesh Gupta serve as directors at the Company.
- CIN/LLPIN
U24231DL1992PTC363074
- Company No.
031641
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 May 1992
- Date of AGM
31 Dec 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Medipol Pharmaceutical India Private Limited offer?
Medipol Pharmaceutical India Private Limited offers a wide range of products and services, including Common Disease Medicines, Antihistamines, Sexual Wellness Products, Female Hygiene Products & Test Kits, Psoriasis Ointment, Pharmaceutical Syrup, Anti Infective Drugs & Medicines, Antibiotic Tablets, Capsule & Syrup, Hand Sanitizers & Personal Hygiene, Antiseptic Liquid & Cream.
Who are the key members and board of directors at Medipol Pharmaceutical India?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Umesh Gupta  | Director | 01-Mar-2004 | Current |
| Sanjay Agarwal | Director | 07-Dec-2023 | Current |
| Yogesh Gupta | Director | 11-Oct-1999 | Current |
Financial Performance of Medipol Pharmaceutical India.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Medipol Pharmaceutical India?
Unlock access to Medipol Pharmaceutical India's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 24 Jan 2011 | ₹20.90 Cr | Open |
State Bank Of India Creation Date: 16 Jan 2008 | ₹5.80 Cr | Satisfied |
State Bank Of India Creation Date: 16 Jan 2008 | ₹7.30 M | Satisfied |
How Many Employees Work at Medipol Pharmaceutical India?
Unlock and access historical data on people associated with Medipol Pharmaceutical India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medipol Pharmaceutical India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medipol Pharmaceutical India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
